YOLFTbeta
Sequana Medical NV

Sequana Medical NV

SEQUA · BR · Healthcare / Medical Devices

0.611EUR+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.611
Open0.669
Day Range0.56 – 0.669
52-Week Range0.46 – 0.877
Volume0
Market Cap47.76M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.23
Dividend Yield0.00%
Beta-0.30
50-Day Avg0.611
200-Day Avg0.5836

About

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Ian Crosbie
  • Employees48
  • HeadquartersKortrijksesteenweg 1112, Gent, Belgium, 9051, Belgium
  • Websitehttps://www.sequanamedical.com

Leadership

  • Mr. Ian CrosbieCEO & Executive Director
  • Ms. Kirsten Van BockstaeleChief Financial Officer · b. 1975
  • Dr. Gijs Klarenbeek M.D.MD & Chief Medical Officer · b. 1977
  • Mr. Martijn BlomChief Commercial Officer · b. 1974
  • Mr. Mark SingerHead of U.S. Commercial

Financials

Income Statement

Currency: EUR2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Total Revenue1.68M1.49M1.30M1.03M970.64K963.28K370.50K922.69K712.17K106.00K
Growth (%)--11.64%-12.41%-21.07%-5.69%-0.76%-61.54%+149.04%-22.82%-85.12%
Cost of Revenue359.24K320.41K212.43K158.06K197.76K202.41K76.66K204.60K164.12K26.44K
Gross Profit1.33M1.17M1.09M871.12K772.88K760.87K293.84K718.09K548.05K-2.22M
Gross Margin78.68%78.48%83.71%84.64%79.63%78.99%79.31%77.83%76.95%-2092.45%
Operating Expense12.75M14.91M8.66M13.91M14.84M18.22M22.94M28.81M30.04M16.49M
Operating Income-11.42M-13.74M-7.57M-13.04M-14.07M-17.45M-22.65M-28.09M-29.49M-18.71M
Operating Margin-677.99%-923.17%-580.63%-1266.82%-1449.65%-1811.99%-6113.17%-3044.86%-4141.05%-17647.17%
EBITDA-11.38M-13.66M-7.49M-13.02M-13.83M-17.57M-22.24M-29.19M-29.14M-17.39M
EBITDA Margin-675.23%-917.79%-574.66%-1264.68%-1424.51%-1823.67%-6002.90%-3164.05%-4091.26%-16409.43%
Net Income-11.56M-13.97M-8.23M-13.98M-14.98M-19.11M-23.62M-30.76M-32.56M-44.65M
Net Income Margin-685.89%-938.67%-630.78%-1358.69%-1543.05%-1983.45%-6373.84%-3334.08%-4572.42%-42126.42%
R&D994.97K1.15M1.17M934.80K2.52M1.86M6.14M7.71M5.28M1.68M
R&D as % of Total Revenue59.05%77.00%90.02%90.83%259.69%193.02%1657.28%835.26%741.02%1587.68%
Interest Expense88.51K190.11K635.51K921.96K770.59K1.08M572.51K879.96K4.29M26.36M
Interest Expense % of Total Revenue5.25%12.77%48.74%89.58%79.39%111.67%154.52%95.37%602.10%24870.75%

Balance Sheet

Currency: EUR2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Total Assets6.04M4.68M3.81M3.52M3.34M9.35M14.21M14.71M26.03M10.10M9.94M
Total Liabilities3.19M4.97M10.48M8.13M22.10M8.42M14.10M15.49M28.18M29.57M54.32M
Total Equity2.85M-284.66K-6.67M-4.61M-18.76M925.93K112.76K-786.92K-2.15M-19.47M-44.38M
Cash4.09M1.43M797.46K1.68M1.32M5.59M11.02M9.60M18.87M2.58M3.81M
Total Debt--4.66M4.58M14.65M3.22M7.86M8.09M17.59M17.52M40.11M
Net Debt-4.09M-1.43M3.87M2.89M13.34M-2.36M-3.16M-1.52M-1.28M14.94M36.30M

Cash Flow

Currency: EUR2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Operating Cash Flow-11.26M-12.75M-8.69M-9.88M-18.48M-17.01M-23.62M-27.48M-29.06M-20.26M
Investing Cash Flow-108.08K-217.03K-10.30K-54.88K-337.02K-142.03K-338.20K-653.09K-721.37K-100.00K
Financing Cash Flow8.22M12.24M9.81M9.47M23.22M22.63M22.44M37.32M13.46M21.56M
Capital Expenditure88.81K214.69K6.52K38.62K333.02K138.02K325.78K676.74K710.75K95.00K
Free Cash Flow-11.35M-12.96M-8.70M-9.91M-18.82M-17.14M-23.94M-28.16M-29.77M-20.52M
FCF to OCF100.79%101.68%100.08%100.39%101.80%100.81%101.38%102.46%102.45%101.27%

Earnings

Report DateJan 31, 2019Apr 4, 2019Sep 25, 2019Mar 19, 2020Sep 3, 2020Mar 17, 2021Sep 2, 2021Dec 1, 2021Apr 26, 2022Sep 8, 2022Nov 30, 2022Feb 8, 2023May 31, 2023Sep 14, 2023Nov 29, 2023Mar 28, 2024May 23, 2024Sep 30, 2024Nov 27, 2024Mar 18, 2025Apr 22, 2025Sep 25, 2025Dec 3, 2025Mar 25, 2026
EPS Estimate0.000.000.000.000.000.00-0.66-0.32-0.32-0.68-0.32-0.32-0.35-0.65-0.30-0.57-0.29-0.15-0.14-0.12-0.12-0.08-0.07-0.07
EPS Actual-0.14-0.42-0.61-1.19-0.62-1.21-0.66-0.32-0.19-0.68-0.32-0.21-0.35-0.65-0.30-0.57-0.18-0.34-0.15-0.12-0.82-0.350.000.00
Surprise------0.00%0.00%40.63%0.00%0.00%34.38%0.00%0.00%0.00%0.00%37.93%-126.67%-7.14%0.00%-583.33%-337.50%100.00%100.00%
Timing-Pre-market-After-hoursPre-marketPre-marketPre-market-After-hours--After-hours----Pre-market-------

Key Statistics & Ratios

Market Cap47.76M
Enterprise Value81.85M
Trailing P/E0.00
Forward P/E0.00
Price / Sales473.50
Price / Book9.22
EPS-1.23
Book Value-0.685
Revenue (TTM)0
Gross Profit (TTM)-355
EBITDA-17.20M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-690.43%
Return on Assets-88.40%
Shares Outstanding78.17M
Shares Float36.96M
Beta-0.30
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%